Sources of Cannabis Information and Medical Guidance for Neurologic Use
NARCOMS Survey of People Living With Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 18, 2021
- Accepted January 5, 2022
- First Published January 20, 2022.
Article Versions
- Previous version (January 20, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Amber Salter, PhD,
- Gary Cutter, PhD,
- Ruth Ann Marrie, MD, PhD,
- Kathryn Nichol, PhD,
- Joshua R. Steinerman, MD,
- Karry M.J. Smith, PhD, MPH and
- Robert J. Fox, MD
- Amber Salter, PhD,
(1) DSMB for Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2 (2) OSMB for Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis
NONE
NONE
Circulation: Cardiovascular Imaging, Statistical Editor, 2018- 2021 Neurology, Editorial board member, 2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Department of Defense, Principal Investigator, 2021-2024
NONE
(1) Consortium of Multiple Sclerosis Centers (2) National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Gary Cutter, PhD,
Data and Safety Monitoring Boards: AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Immunic, Mapi Pharmaceuticals LTD, Merck, Merck/Pfizer, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, Teva pharmaceuticals, VielaBio Inc, , NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee).
NONE
NONE
Multiple Sclerosis Journal: editorial board, (11 yrs); Multiple Sclerosis and Related Disorders: Editorial board; (1 yr);Am journal of the Society of Nephrology. Statistical editor; contributing statistical help (6 yrs); Alzheimer's and Dementia (5) yrs; Neurology Clinical Practice (7yrs);
NONE
NONE
NONE
Alexion, Antisense Therapeutics, Biogen, Clinical Trial Solutions LLC, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio/Horizon Pharmaceuticals, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Protalix Biotherapeutics, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche.Therapeutics.
NONE
President of Pythagoras Inc. a consulting company
NONE
NONE
U01 AR071133 (Bammam) 12/6/2016  11/30/2022 6 calendar NIH/NIAMS $ 6,942,009 (total funds) The Exercise and Physical Activity Collaborative Team (ExPact): A Proposed MoTrPAC Clinical Center The goals are to help lead the NIH Common Fund initiative  Molecular Transducers of Physical Activity Consortium (MoTrPAC)  by serving as one of six adult clinical centers conducting a large-scale, randomized, controlled trial (RCT) of resistance vs. aerobic exercise training vs. no-exercise control. The RCT will be complemented by molecular acute response studies in RCT participants as well as highly trained athletes; all with the goal of generating molecular maps that reveal key underpinnings of exercise-induced health benefits. No Number (Motl) 01/01/2020  06/30/2021 .87 calendar Consortium of Multiple Sclerosis Centers $39,996 total costs Examining Patterns and Correlates of Wellness in Persons with Multiple Sclerosis who use Wheelchairs 5U54NS115054 (PI: Kaminski, sub-PI: Cutter) 09/01/2019  05/31/2024 0.6 calendar NIH/NINDS $321,265 total costs Rare Disease Network for Myasthenia Gravis We propose development of the Myasthenia Gravis Clinical Research Consortium (MGNet) to coordinate investigators in collection of detailed clinical information and biological specimen along with performance of pilot investigations of a therapeutic and biomarker discovery. We link our efforts to a program to develop new investigators in myasthenia gravis. This is all done with the purpose of enhancing performance clinical trials and care of patients to one day find a cure for myasthenia gravis. 5R01AG057684 (Kennedy) 09/15/2017  03/31/2022 0.12 calendar NIH/NIA $3,242,015 total costs In Silico Screening of Medications for Slowing AlzheimerÂs Disease Progression In this proposal, we will explore drug repurposing, in which medications approved to treat other illnesses are evaluated for potential benefits in Alzheimer's disease (AD), to improve the efficiency of the drug development process, which currently ends in failure for most candidate medications despite considerable investment of both time and resources. We will apply data mining, or pattern recognition, algorithms to the concomitant medications taken by subjects in previous AD clinical trials that are part of our meta-database of more than 6,500 individuals and by participants in Medicare Part D with more than 787,000 individuals. This approach will allow us to screen hundreds of drugs for effects in slowing the progression of AD, which will guide future clinical trials of novel therapeutic agents. 1U01HL119242 (PI: Szychowski) 09/01/2014  11/30/2021 .96 calendar NIH/NHLBI $2,744,642 total costs Chronic Hypertension and Pregnancy (CHAP): Data Coordinating Center CHAP is a pragmatic multi-center randomized trial of pregnant women with mild chronic hypertension to evaluate the benefits and harms of antihypertensive therapy to a goal <140/90 mmHg (as recommended for the general population in the US) compared with ACOGÂs current policy of expectant management of mild chronic hypertension in pregnancy. The trial will enroll 2,404 women across more than 60 clinical sites. R01HD098132-01A1 (PI: Subramaniam) 01/20/2020  12/31/2024 .24 calendar NIH/NICHD $3,242,752 total costs Childhood Pulmonary and Related Outcomes after Perinatal Exposure to Adjunctive Azithromycin Prophylaxis for Cesarean Delivery (C/SOAP Follow-Up Study) We propose a US multi-center long-term follow-up study of children from the parent C/SOAP trial at age 6-8 years to evaluate childhood respiratory and gastrointestinal health effects after perinatal exposure to adjunctive azithromycin; findings from this study will be used to inform and strengthen national and global health care policy regarding the use of adjunctive azithromycin to reduce maternal infection after cesarean delivery. R01AI148359 (PI: Geisler) 05/11/2020  04/30/2025 0.6 calendar NIH/NIAID $3,201,254 total costs Host Immune Responses to Chlamydia trachomatis Candidate Vaccine Antigens and their Association with Clinical Correlates of Protective Immunity in Women Current chlamydia prevention and control efforts have been unable to reduce chlamydia infection rates, which provides strong rationale for development of a chlamydia vaccine to prevent chlamydia and its reproductive sequelae. This project will evaluate systemic and mucosal cellular and humoral immune responses induced by promising chlamydia vaccine candidate antigens and will assess association of the immune responses with clinical correlates of protection against chlamydia in women (spontaneous clearance of chlamydia and absence of reinfection after treatment). Findings may advance chlamydia vaccine development efforts and lead to formulation of these candidate antigens into a chlamydia vaccine for a phase I study. 5U01NS092595 (PI: Bebin) 06/01/2016  05/31/2022 0.24 calendar NIH/NINDS $7,084,395 total costs Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex This study focuses on the developmental impact of early vigabatrin treatment in infants with Tuberous Sclerosis Complex who are at risk of developing epilepsy. Also, the study aims to determine the effectiveness of early vigabatrin treatment in clinical seizure prevention and its impact on the development of drug resistant epilepsy at 24months of age. This is the first seizure prevention trial in patients with TSC in the United States. 1R01HD088646 (PI: Katheria, sub PI: Szychowski) 04/01/2017- 03/31/2022 0.6 CM NIH/NCHHD $547,854 (total funds) Premature Infants Receiving Cord Milking Or Delayed Cord Clamping Delayed cord clamping reduces overall bleeding in the brain of premature infants, but not the most severe types. ÂMilking the umbilical cord, a method used to transfer blood from the placenta into the baby before the umbilical cord is clamped, may provide additional blood volume to the brain and other vital organs thereby reducing bleeding in the brain and improving long-term outcomes in premature babies. This study will determine whether umbilical cord milking reduces bleeding in the brain or death in premature newborns delivered by Cesarean section compared to delaying clamping of the umbilical cord. P30DK079337 (PI: Agarwal) 08/01/2018  07/31/2023 1.77 CM NIH/NIDDK $1,136,699 (total funds) OÂBrien Center for Acute Kidney Injury Research Acute kidney injury (AKI) is a major cause for morbidity and mortality in hospitalized patients and is being increasingly recognized as a cause for chronic kidney disease. AKI doubles the length of stay in the hospital, increasing health care resources. The UAB-UCSD O'Brien Center has brought together a team of investigators to serve unmet needs of our investigator base and to fill the gaps in knowledge in the field of AKI and AKI-related research. K23HD091849 (Gerstenecker) 09/12/2018  08/31/2023 0 calendar, Co-Mentor NIH/NICHHD $630,875 total costs Investigating the Impact of Cognition on Capacity in Multiple Sclerosis At a time in which increased cognitive ability is needed to make complex financial and medical decisions, people with MS are often experiencing cognitive decline; surprisingly though, research into the ability of people with MS to make complex financial and medical decisions is rare. This study proposes to investigate financial and medical decisional capacity and its clinical and neuroanatomical correlates in people with relapsing- remitting MS and progressive MS. The ultimate value of this research will be to act as a necessary first-step in the development of a targeted capacity rehabilitation program for people diagnosed with MS. K23HL127100 (Lebensburger) 04/01/2015  03/31/2021 0 calendar, Mentor NIH/NHLBI $916,445 total costs Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy Hypertension is a known risk factor for stroke in sickle cell disease and in other diseases associated with adverse cardiovascular outcomes. Within the context of a feasibility trial, this proposal will develop vital background data to understand the acceptability of, adherence to, and dosing strategy for losartan prior to conducting a definitive trial for adolescent sickle cell disease patients with abnormal circadian blood pressure. A prospective cohort study will also be conducted to define the relationship of urine and blood biomarkers on the development of abnormal nocturnal blood pressure dipping and kidney injury. PENDING OSP 532909 (Lal) 04/01/2022  03/31/2027 0.6 CM NIH $935,194 Optimization of Saturation Targets and Resuscitation Trial (OptiSTART) R34HL157412 (Leesar) 04/01/2021  03/31/2024 0.6 CM NIH/NHLBI $668,250 total costs Effects of Crushed Ticagrelor and no Fentanyl Versus Eptifibatide Bolus+Ticagrelor and Fentanyl in Patients with NSTE-ACS Undergoing Early PCI: A randomized Trial (CTEP trial) R21HD104996 (Rogers) 09/01/2021  08/31/2023 0.6 CM NIH $408,375 total costs Microbiome as a Novel Mechanism of Exercise Training Effects in Multiple Sclerosis R01HL154109 (Sanders) 04/01/2021  03/31/2026 0.6 CM NIH/NHLBI $2,929,087 total costs Dietary Sodium & Potassium and Aortic Stiffness R01TR003741 (Danila) 04/01/2021  03/31/2024 0.6 CM NIH/NCATS $2,937,048 total costs Digital Health for Rheumatology Care in COVID19 Era OSP 532630 (Motl) 06/01/2021  05/31/2024 0.6 CM Bristol-Myers Squibb Foundation, Inc. $770,799 total costs Exercise Promotion and Outcomes Among African-Americans with Multiple Sclerosis Living in Rural Communities OSP 533051 (Leesar) 04/01/2022  03/31/2025 0.6 CM NIH/NHLBI $668,250 total costs Platelet Inhibition with Crushed Ticagrelor versus Eptifibatide Bolus in Patients with Non-ST-Segment Elevation Myocardial Infarction undergoing Ad Hoc PCI with no Opiods R01HD108618 (Taub) 04/01/2022  03/31/2024 0.6 CM NIH/NCHHD $1,183,924 total costs A Therapy for Long COVID Brain Fog and Cognitive Impairment U24HL155807 (Aban) 07/01/2021  06/30/2027 0.6 CM NIH/NHLBI $1,844,073 total costs 2/2 Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease (Tele-COPD) R01AG070049 (Taub) 08/01/2021  07/31/2025 0.6 CM NIH/NCHHD $2,312,394 total costs Transferring Speed of Processing Gains to Everyday Cognitive Tasks after Stroke R01DK131079 (Novak) 12/01/2021  11/30/2026 1.2 CM NIH/NIDDK $3,764,635 total costs Unraveling Clinical and Pathophysiologic Disparities in African Americans with IgA Nephropathy) To address the historic lack of research into this chronic disease in African American patients, we will identify the first large, well-characterized, cohort of African American patients with IgA nephropathy and will assess factors associated with their disease pathogenesis, severity, and progression. Role: Co-Investigator K23DK131291 (Farrington) 09/01/2021  08/31/2026 no effort, consultant NIH/NIDDK $943,378 The Role of the Immune System in Arteriovenous Fistula Failure OSP 531819 (Agarwal) 06/01/2021  05/31/2025 0.6 CM NIH $2,830,956 Biological and Clinical Characterization of Kidney Patients Post-Acute Covid19 (BACKPAC) OTA-21-015B OSP 532702 (Aban) 02/01/2022  01/31/2028 0.6 CM NIH $281,882 Early Epilepsy Surgery in Tuberous Sclerosis Complex
NONE
The MG Registry receives funding from the Myasthenia Gravis Foundation of America
Consortium of MS Centers - Past President - only expenses covered
NONE
NONE
NONE
NONE
NONE
- Ruth Ann Marrie, MD, PhD,
NONE
NONE
NONE
Multiple Sclerosis Journal, Editorial Board Multiple Sclerosis Journal-ETC, Co-Editor (ended Dec 2020)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Roche (no direct funding to me), Biogen (no direct funding to me)
Received support as principal investigator from the Canadian Institutes of Health Research (2010-2022), and Research Manitoba (2014-2022) and as co-investigator from US Department of Defense (2020-2023).
Waugh Family Chair in Multiple Sclerosis
Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2022) and the National Multiple Sclerosis Society (2013-2021), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2021). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014, 2016-2022), Crohn's and Colitis Canada (2014- 2022), The Arthritis Society (2021-2022)
NONE
NONE
NONE
NONE
NONE
NONE
- Kathryn Nichol, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
1) Currently employed at LivaNova since Oct 2021 2) Previously employed at Greenwich Biosciences (Jazz/GW) from June 2015 to Oct 2021 Stock/Stock Options, Medical Equipment & Materials: 1) Greenwich Biosciences, June 2015 to Oct 2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joshua R. Steinerman, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Greenwich Biosciences, Vice President, Neuropsychiatry, 2020- 2021
Click Therapeutics Stock/Stock Options, Medical Equipment & Materials: (1) Jazz Pharmaceuticals 2021, (2) GW Pharmaceuticals 2020- 2021, (3) Click Therapeutics 2020-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Karry M.J. Smith, PhD, MPH and
NONE
NONE
Spouse has received reimbursement for travel related to consulting for Medtronic, Boston Scientific, Abbott (formerly St Jude), and Regenexx. Funds from each company amount to approximately less than $10K USD each.
NONE
NONE
NONE
Self, currently employed by Merck (US), managing medical writer, Sep 2021-present Self, formerly employed by GW Pharma/Jazz, senior manager medical writing, July 2019-Aug 2021 (directly related to this manuscript).
See consultancies for spouse listed above in Q3. Stock/Stock Options, Medical Equipment & Materials: The following were not sponsors of this research, but we do hold stock in these companies. Self - GW Pharma 2019-2021, Jazz Pharmaceuticals 2021-present, Merck (US) 2021-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert J. Fox, MD
AB Science, Biogen, Genzyme, Immunic, Janssen, Novartis, and Sanofi
NONE
NONE
Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal
NONE
Multiple Sclerosis and Related Disorders, Demos Medical, 2019
NONE
AB Science, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Greenwich Biosciences, Immunic, Janssen, Novartis, Sanofi, and TG Therapeutics
NONE
NONE
NONE
Research contracts from Biogen, Novartis, and Sanofi.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- UT Southwestern Medical Center (AS), Dallas, TX; The University of Alabama at Birmingham (GC); Max Rady College of Medicine (RAM), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; Greenwich Biosciences, Inc. (KN, JRS, KMJS), Carlsbad, CA; and Mellen Center for Multiple Sclerosis (RJF), Cleveland Clinic, OH.
- Correspondence
Dr. Salter amber.salter{at}utsouthwestern.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.